Lupin Receives US FDA EIR for Somerset Facility with VAI Classification

Lupin Limited announced it has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Somerset, New Jersey. The facility received a Voluntary Action Indicated (VAI) classification following an inspection conducted from April 13-17, 2026. This positive outcome underscores Lupin's commitment to quality and compliance in its manufacturing operations. The VAI classification indicates that while some observations may have been made, they do not warrant regulatory action beyond the company's own corrective measures.